Cutting-Edge PET/CT Scanner Is Clinically Operational

Publication
Article
OncologyONCOLOGY Vol 16 No 6
Volume 16
Issue 6

The world’s first clinically operational molecular imager with lutetium oxyorthosilicate (LSO) technology-the biograph LSO, manufactured by Siemens Medical Solutions-has produced a precisely registered, combined positron-emission tomography (PET)/computed tomography (CT) image in 7 minutes at the Hong Kong Baptist Hospital. The biograph LSO imager uses the high-speed properties of LSO as the PET scintillator to provide shorter scan times and unmatched patient throughput.

The world’s first clinicallyoperational molecular imager with lutetium oxyorthosilicate (LSO) technology—thebiograph LSO, manufactured by Siemens Medical Solutions—has produced aprecisely registered, combined positron-emission tomography (PET)/computedtomography (CT) image in 7 minutes at the Hong Kong Baptist Hospital. Thebiograph LSO imager uses the high-speed properties of LSO as the PETscintillator to provide shorter scan times and unmatched patient throughput.

The biograph LSO merges three components—the ECAT ACCEL PETscanner, the SOMATOM Emotion spiral CT scanner, and syngo multimodality software—intoa powerful scanning device that creates a precisely registered molecular imagein 15 minutes or less. The resulting image makes it possible for oncologists andother health-care providers to view detailed anatomy and the biologicalprocesses of internal organs and living tissue at the molecular level in asingle, noninvasive diagnostic procedure.

In addition to the biograph LSO, the biograph is available with bismuthgermanate (BGO) crystal technology—a proven and economic scintillator forquality high-resolution PET imaging. The first commercial installation of thebiograph with BGO technology was completed last fall at Memorial Sloan-KetteringCancer Center in Manhattan.

Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content